发现和表征RGH-122,一个强大的,选择性的,口服可生物利用的V1a受体对手
Ferenc Baska1, Éva Bozó1, Zsolt Szeleczky1
1Gedeon Richter Plc, PO Box 27, Budapest H-1475, Hungary.
Journal of medicinal chemistry
|January 2, 2024
概括
研究人员开发了一种新的V1a抗剂,RGH-122,用于治疗神经精神疾病. 这种化合物在自闭症模型中成功增强了社会偏好,显示出治疗社会缺陷的前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 氨酸-血管压素 (AVP) 通过V1a受体影响社会和情绪行为.
- V1a受体是神经精神疾病的潜在治疗点.
研究的目的:
- 设计和合成新的,选择性的V1a受体抗剂.
- 确定一种具有改善体外和体内疗效的临床候选药物.
主要方法:
- 为了优化,进行了结构-活性关系 (SAR) 研究.
- 低纳米分子抗剂是通过代设计和合成开发的.
- 化合物43 (RGH-122) 被确定为临床候选物.
- 在自闭症模型中使用三室社会偏好测试来评估体内中枢神经系统 (CNS) 活动.
主要成果:
- 合成了具有低纳米分子功率的新型V1a抗剂.
- 化合物43 (RGH-122) 在体外和体内表现出有前途的特征.
- 在自闭症模型中,RGH-122显著增强了社会偏好.
- 在社会偏好测试中,RGH-122的最低有效剂量为1.5 mg/kg.
结论:
- 包括RGH-122在内的选择性V1a抗剂代表了神经精神疾病的有前途的治疗策略.
- RGH-122具有治疗与自闭症谱系障碍相关的社会缺陷的潜力.
- 根据其在临床前模型中的疗效,需要进一步开发RGH-122.
相关概念视频
Drug-Receptor Interaction: Antagonist
3.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
3.0K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
882
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
882
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
819
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
819
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Structure-Activity Relationships and Drug Design
726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726


